Friday, October 2, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Earnings callYahoo Finance· November 18, 2025

Navios NMM Earnings Call Transcript

View original at finance.yahoo.com
Navios NMM Earnings Call Transcript Image source: The Motley Fool. Date Tuesday, Nov. 18, 2025 at 8:30 a.m…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • 234 Capesize vessels needed for new iron ore capacity, but only 173 vessels in current order book

    80% confidence
  • Company is laser-focused on business and modernizing fleet

    80% confidence
  • Tanker market outlook is positive over medium term based on low order book, aging fleet, reduced fleet from sanctions

    80% confidence
  • Drybulk market outlook is positive based on steady long-term demand growth and constrained vessel supply

    80% confidence
  • Tariffs not expected to significantly affect tankers/drybulk except steel; reduced container/grain impact expected post US-China trade deal

    80% confidence
  • Geopolitical risk, regional conflict, tariff changes, and evolving trade patterns are unprecedented

    80% confidence
  • Sanctioned tankers total 785 vessels, representing approximately 14% of total capacity removed

    80% confidence
  • Diversification is strength when embedded in risk management culture

    80% confidence
  • EBITDA run rate of approximately €750M over past 4 years

    80% confidence
  • Five years of constant change in operating environment driven by geopolitical events

    80% confidence
  • Company has strong risk management culture, continuously monitoring and assessing risk

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com